Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. (1/29)
The disposition and metabolism of pentamethylmelamine (PMM) and hexamethylmelamine (HMM) were studied in the rabbit, and the disposition of PMM was studied in humans. Parent compound and metabolites were identified by thin-layer chromatography, gas chromatography, and gas chromatography/mass spectrometry analyses. Plasma elimination in both species following i.v. administration of each drug was best described by a two-compartment open model. Both compounds were extensively demethylated with less than 1% of the total dose administered recovered in the urine over 24 hr. The areas under the plasma time-concentration curves of PMM and HMM following p.o. administration to rabbits were 5 and 25% of the areas following i.v. administration. Gastrointestinal absorption was rapid and efficient with 75 to 89% of drug equivalents recoverable in the urine after p.o. administration of [ring-14C]PMM or [ring-14C]HMM to rabbits. Reduced bioavailability of PMM and HMM p.o. appears to be a consequence of rapid metabolism presumably in the liver. (+info)Recurrent ovarian cancer: how important is it to treat to disease progression? (2/29)
Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response. Despite the large proportion of patients who relapse and undergo longer-term treatment, the question of optimal treatment duration has not been fully addressed to date. For patients who progress on therapy, the answer is straightforward: they are switched to another active agent, presumably having a different mechanism of action from previous therapies with, ideally, limited overlapping toxicities. However, for patients who remain in partial response or who have stable disease, the answer is less apparent and less clear. The majority of oncologists believe that treatment beyond 6 cycles of a given therapy does not provide any additional benefit to patients. There are some data to support that treatment strategy. However, with the advent of new, less toxic agents, treatment to progression should be further explored. Agents that are potentially well suited for extended treatment intervals may include such properties as absence of cumulative toxicity, non-cross-resistance, positive benefit on quality of life, and convenient schedule. A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment. (+info)Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. (3/29)
PURPOSE: A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if the baseline CA-125 level before initiation of maintenance chemotherapy in women achieving a clinically-defined complete response to primary chemotherapy would be of prognostic value. PATIENTS AND METHODS: Patients included in this retrospective analysis had been treated on one of two previously reported trials of maintenance chemotherapy (three v 12-monthly cycles of paclitaxel; oral altretamine), with a baseline CA-125 level of < or = 35 u/mL. Progression-free survival (PFS) from study entry was analyzed by the Cox regression model. RESULTS: The distribution of premaintenance baseline CA-125 levels for the 384 patients was 58%, 34%, and 8% for values of (A) < or = 10 u/mL, (B) 11 to 20 u/mL, and (C) 21 to 35 u/mL, respectively. The baseline CA-125 was highly statistically significant, either as a categoric variable (P < .001) or as a continuous variable (P < .0001). Median PFS was 24 months, 17 months, and 7 months for groups (A), (B), and (C), respectively. There was no evidence the CA-125 effect differed by trial or treatment in an interaction analysis (P = .70). CONCLUSION: The baseline CA-125 level before initiation of maintenance chemotherapy strongly predicts the risk of subsequent relapse. Patients with premaintenance baseline CA-125 values < or = 10 u/mL have a superior PFS compared with higher levels in the normal CA-125 range. (+info)Relationship between frailty and cognitive decline in older Mexican Americans. (4/29)
(+info)Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer. (5/29)
Forty-six patients with recurrent ovarian cancer were reoperated, and cancer samples for the subrenal capsule assay (SRCA) were collected from 23 of them, whereas this test was not done in the remaining 23 control patients. The SRCA was evaluable in 22 cases (96%). Taken together, no significant difference appeared in the 3 years' survival figures between the groups: seven of 22 patients (32%) with the evaluable SRCA and six of 23 control patients (26%) were alive. However, a further analysis of the data revealed that the SRCA guided the selection of chemotherapy only in 15 patients, whereas tumour samples were resistant to all cytostatics tested in six cases and toxic side-effects limited the clinical application of the test results in the remaining one case. Four of the 11 patients (36%) whose further chemotherapy was strictly chosen based on the SRCA and seven of the 24 patients (29%) whose treatment was based on physician's choice survived at least 3 years. Our conclusion is that the SRCA is of limited value in the selection of second-line chemotherapy in recurrent ovarian cancer. (+info)Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. (6/29)
Long-term follow-up was obtained on 726 women with advanced ovarian carcinoma (suboptimal stage III and stage IV) who had received primary chemotherapy on two Gynecologic Oncology Group (GOG) protocols between 1976 and 1982. The first study compared melphalan alone versus melphalan plus hexamethylmelamine versus cyclophosphamide plus doxorubicin (CA). The second study evaluated the same CA regimen with or without cisplatin. Eligibility for the two studies was the same. At last contact, 76 patients were alive. In a multivariate analysis, cell type other than clear cell or mucinous, cisplatin-based treatment, good performance status, younger age, lower stage, clinically nonmeasurable disease, smaller residual tumor volume, and absence of ascites were favorable characteristics for overall survival (P less than .05). Second-look laparotomy was negative significantly more often among those with endometrioid tumors; there were no negative second-look laparotomies among those with mucinous or clear cell tumors. There were 30 patients with suboptimal stage III disease who had a negative second-look laparotomy; 18 (60%) have experienced recurrence, and 13 (43%) have died. Although cisplatin treatment was beneficial, new treatments are clearly needed. (+info)Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy. (7/29)
(+info)Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). (8/29)
The data on 914 patients enrolled in four randomised trials in advanced ovarian cancer, consecutively conducted by the same cooperative group between 1978 and 1986, were analysed with the aims of: (1) determining the impact of selected prognostic variables on survival; (2) finding, from the interaction of favourable prognostic factors and treatment, an approximate estimate of the magnitude of the survival advantage associated with the use of platinum-based combination chemotherapy. The overall 3-year survival in this series of patients is twice that reported historically (22%; 95% CL 18.7-25.4). The proportional hazard regression model was used to perform the analysis on survival. Residual tumour size, age, FIGO stage and cell type were all independent determinants of survival. Differences in survival from the various prognostic groups were impressive with 5-year survival rates ranging from 7 to 62%. However, these differences were not qualitative (i.e. the kinetics of survival were similar for the best and the worst groups) suggesting that current prognostic factors are of little use for selecting 'biologically' different sub-populations. Platinum-based regimens were associated to an overall prolonged median survival, but this benefit was not observable in the subgroup with most favourable prognosis (less than 2 cm residual tumour size). The implications of these observations for clinical research and ovarian cancer patients care are discussed. (+info)Hexamethylmelamine-A new drug with activity in solid tumors<...
Altretamine and Etoposide in Treating Patients With HIV-Related Cancer - Full Text View - ClinicalTrials.gov
Altretamine capsules
Altretamine capsules
Altretamine capsules
Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer<...
Chemo bandanas - Answers on HealthTap
4-O- substituted isoindoline derivatives and compositions comprising and methods of using the same - Patent application
METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION...
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens - Full Text View -...
E4897 - Archived Educational Materials - ECOG-ACRIN
The Challenges of Risk Perception and Infectious Disease Response: Counteracting Inaccurate Risk Perception | Scowcroft...
Horton, C.
Why are fixed dose combinations of antibiotics generally not a good idea? - 2018 - ReAct
Animal Disease Response Training - Ohio Farm Bureau
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. - PubMed - NCBI
General | Regulation of human neutrophil-mediated cartilage proteoglycan degradation
March | 2017 | Regulation of human neutrophil-mediated cartilage proteoglycan degradation
Development of an Aquatic Emergency Animal Disease Response Agreement - Animal Health Australia
High-intensity Focused Ultrasound (HIFU) As Salvage Therapy For Radio-recurrent Prostate Cancer: Predictors Of Disease Response...
Kansas running animal disease response exercise - Washington Times
Approves Gileads four-drug HIV treatment - tribunedigital-chicagotribune
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its...
Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its...
Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian...
Drug information handbook for oncology : a complete guide to combination chemotherapy regimens (Book, 2013) [WorldCat.org]
GIS online training course «The use of GIS in animal disease response»
Drug combo effective against recurrent ovarian cancer; New oncopig billed as advance for cancer R&D; p53 mechanism could be...
Natural Compounds Block Autoimmune Disease Response in Diabetes and Arthritis - BioTech Weblog
Pembrolizumab shows modest, durable response in recurrent ovarian cancer
CDC pilot programs boost disease response in Uganda, Vietnam | THE OUTBREAK
SENATE BILL NO. 1421, As Amended - Idaho State Legislature
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
Ranitidine - Wikipedia
Plus it
Second-look operation | definition of second-look operation by Medical dictionary
Webcast: Recognizing and Overcoming Challenges in the Treatment of Recurrent Ovarian Cancer | Libbys H*O*P*E*
IM-862 in Treating Patients With Recurrent Ovarian Cancer
Recurrent Ovarian Cancer: Understand Your Treatment Options
Zejula Approved for Recurrent Ovarian Cancer, Primary Peritoneal Cancer - MPR
Ontogeny and disease responses of Langerhans-like cells in lymphoid tissues of salmonid fish | IslandScholar
The Experience of Being Aware of Disease Status in Women with Recurrent Ovarian Cancer: A Phenomenological Study<...
Gilead: Second Trial of 4-Drug AIDS Pill Meets Goal | Fox News
ViiVs Two-Drug HIV Treatment Works Well - POZ
The nephroblastomatosis complex and its relationship to Wilms tumor<...
PhD & MA Essays: Online homework systems plagiarism free!
Setback for Abiraterone Acetate in Recurrent Ovarian Cancer
Second-Look Surgery - procedure, tube, removal, pain, time, infection, medication, cells
Researchers Investigate Dasatinib in Combination with Other Drugs for Advanced, Recurrent Ovarian Cancer | folypeber
HIV/Tuberculosis
Pancreatic Cancer - An Introduction, with Dr. Andrew Ko | Cancer.Net
HMM, YOU MIGHT SAY LONDON
Altretamine
... (trade name Hexalen), also called hexamethylmelamine, is an antineoplastic agent. It was approved by the U.S. FDA ... Malik IA (2001). "Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer". Jpn. J ... ISBN 978-0-7817-6879-5. Drugs.com: Altretamine Monograph Wiernik, P. H.; Yeap, B.; Vogl, S. E.; Kaplan, B. H.; Comis, R. L.; ... The precise mechanism by which altretamine exerts its anti-cancer effect is unknown but it is classified by MeSH as an ...
Lofepramine
Altretamine. Risk of severe drop in blood pressure upon standing. Analgesics (painkillers). Increased risk of ventricular ...
Triethylenemelamine
Altretamine Wong, Jeannette R.; Morton, Lindsay M.; Tucker, Margaret A.; Abramson, David H.; Seddon, Johanna M.; Sampson, ...
Eisai (company)
This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer ...
Melamine
... is part of the core structure for a number of drugs including almitrine, altretamine, cyromazine, ethylhexyl triazone ...
List of drugs: Al
... altretamine (INN) altumomab (INN) Alu-Cap Alu-Tab Aludrox aluminium clofibrate (INN) Alupent (Boehringer Ingelheim) Alustra ...
List of MeSH codes (D03)
... altretamine MeSH D03.383.931.190 - apazone MeSH D03.383.931.247 - atrazine MeSH D03.383.931.320 - ferrozine MeSH D03.383. ...
Alkylating antineoplastic agent
Procarbazine Altretamine Some sources explicitly exclude the triazenes (dacarbazine, mitozolomide, temozolomide) from the ...
ATC code L01
Rucaparib L01XK04 Talazoparib L01XK05 Veliparib L01XK06 Pamiparib L01XX01 Amsacrine L01XX02 Asparaginase L01XX03 Altretamine ...
Index of oncology articles
... altretamine - aluminium sulfate - ALVAC-CEA vaccine - Amanita phalloides - Ambien - amelanotic melanoma - Ames, Bruce - ...
Hemel
... a rugby league club Trade name for altretamine Hemel (film), a 2012 Dutch film Armijn Hemel Mark Hemel (born 1966), Dutch ...
Altretamine: MedlinePlus Drug Information
Altretamine: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking altretamine,. *tell your doctor and pharmacist if you are allergic to altretamine, any other medications, or any ... You should not become pregnant or breast-feed while you are taking altretamine. If you become pregnant while taking altretamine ... Altretamine comes as a capsule to take by mouth. It is usually taken four times a day (a dose after each meal and a dose at ...
A-Z Drug Index for Prescription and OTC Medications
Ovarian Cancer: Practice Essentials, Background, Pathophysiology
Malignant lesions of the ovaries include primary lesions arising from normal structures within the ovary and secondary lesions from cancers arising elsewhere in the body. Primary lesions include epithelial ovarian carcinoma (70% of all ovarian malignancies), germ-cell tumors, sex-cord stromal tumors, and other more rare types.
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with...
Table 2 - Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness,...
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. ...
Mi-Omega NF oral Interactions with Other Medication
Biologics in Cervical Cancer Therapy in: Journal of the National Comprehensive Cancer Network Volume 8 Issue 12 (2010)
... altretamine; 127F, topotecan; 127H, etoposide; 127K, gemcitabine) and the PFS from Gynecologic Oncology Group protocol 227-C ... altretamine; 127F, topotecan; 127H, etoposide; 127K, gemcitabine) and the PFS from Gynecologic Oncology Group protocol 227-C ... altretamine; 127F, topotecan; 127H, etoposide; 127K, gemcitabine) and the PFS from Gynecologic Oncology Group protocol 227-C ... altretamine; 127F, topotecan; 127H, etoposide; 127K, gemcitabine) and the PFS from Gynecologic Oncology Group protocol 227-C ...
Listing of Drugs Currently Regulated as New Drugs (The New Drugs List) - Canada.ca
RxAssist - RXOUTREACH Patient Assist Program
CanMED: HCPCS
Fluad Quadrivalent (influenza virus vaccine quadrivalent, adjuvanted) dosing, indications, interactions, adverse effects, and...
Pediapred (prednisolone sodium phosphate) dose, indications, adverse effects, interactions... from PDR.net
UNII - Q8BIH59O7H
Annexes nationales de médicaments - ANORP
Proposition 65 List of Elabscience Chemicals
US Patent Application for ANTI-cMET ANTIBODY Patent Application (Application #20130109844 issued May 2, 2013) - Justia Patents...
Patent 2830806 Summary - Canadian Patents Database
Buy Dasamaps 70mg Dasatinib Tablet Online at Wholesale Price
National Ambulatory Medical Care Survey, 1997
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated): Uses, Interactions, Mechanism of Action ...
Chemo Induced Nausea and Vomiting - Digital PharmD
Uncategorized - Superior Toxicology & Wellness
Temoside 250 mg Capsule Buy Online at Lowest Price
DOSING REGIMENS OF ANTI-ILT4 ANTIBODY OR ITS COMBINATION WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCER - MERCK SHARP & DOHME
... altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS 184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4- ... altretamine, ifosfamide, procarbazine, mechlorethamine, streptozocin, thiotepa, and pharmaceutically acceptable salts thereof. ... altretamine, carmustine, bendamustine, busulfan, carboplatin, lomustine, cisplatin, chlorambucil, cyclophosphamide, dacarbazine ...
Ovarian Cancer: Practice Essentials, Background, Pathophysiology
Malignant lesions of the ovaries include primary lesions arising from normal structures within the ovary and secondary lesions from cancers arising elsewhere in the body. Primary lesions include epithelial ovarian carcinoma (70% of all ovarian malignancies), germ-cell tumors, sex-cord stromal tumors, and other more rare types.
DeCS
Table 2 - Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness,...
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. ...
Code System Concept
Hexalen2
- altretamine (hexalen). (ketyfranzolin.com)
- Instead, he was mistakenly ordered the chemotherapy drug, Hexalen (altretamine). (medaware.com)
Medications3
- Altretamine is used to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) that has not improved or that has worsened after treatment with other medications. (medlineplus.gov)
- Altretamine is a medication that is in a class of medications called antineoplastic agents. (medlineplus.gov)
- tell your doctor and pharmacist if you are allergic to altretamine, any other medications, or any of the ingredients in altretamine capsules. (medlineplus.gov)
Cisplatin1
- Rejunuron Plus Injection 2 ml may interact with anti-cancer drugs (altretamine, cisplatin), fits medicines (phenytoin, phenobarbital), antibiotics (chloramphenicol), and medicines treating Parkinson's disease (levodopa). (apollopharmacy.in)
Capsule1
- Altretamine comes as a capsule to take by mouth. (medlineplus.gov)
Include1
- Possible drug interactions include: Altretamine. (jacanswers.com)
Drug1
- Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais. (napra.ca)
Doctor4
- Your doctor will order certain tests before and during your treatment to check your body's response to altretamine. (medlineplus.gov)
- Your doctor may adjust your dose of altretamine depending on your response to treatment and any side effects that you experience. (medlineplus.gov)
- Do not stop taking altretamine without talking to your doctor. (medlineplus.gov)
- If you become pregnant while taking altretamine, call your doctor. (medlineplus.gov)
Hexamethylmelamine3
- Altretamine is an orally administered alkylating agent, formerly known as hexamethylmelamine, which is currently used as a secondary therapy for advanced ovarian carcinoma. (nih.gov)
- Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. (nih.gov)
- 15. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer. (nih.gov)
Cisplatin2
- Altretamine is FDA approved as a single agent for the treatment of ovarian cancer that has stopped responding to previous therapy with a cisplatin and/or alkylating-based chemotherapy regimen. (thegiconnection.com)
- Before using this product, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: altretamine, cisplatin, certain antibiotics (e.g., chloramphenicol), certain anti-seizure drugs (e.g., phenytoin), levodopa, other vitamin/nutritional supplements. (ndrugs.com)
Capsules1
- tell your doctor and pharmacist if you are allergic to altretamine, any other medications, or any of the ingredients in altretamine capsules. (medlineplus.gov)
Ovarian cancer2
- Altretamine is used for Ovarian Cancer and other conditions. (earthlinglifesciences.com)
- Altretamine is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms like Ovarian Cancer. (earthlinglifesciences.com)
Antineoplastic Agents1
- Altretamine is a medication that is in a class of medications called antineoplastic agents. (medlineplus.gov)
Meen1
- Altretamine (al tret' a meen) is a synthetic, orally available alkylating agent belonging to the methylmelamine class of these agents. (nih.gov)
Moderate2
- Altretamine: moderate salicylates or links external factors. (chenuzbois.ch)
- Altretamine: moderate monitor patients with antibiotic resistance to the dose b. (michiganslipandfalllawyers.com)
Serum2
- Altretamine therapy has been associated with low rates of serum enzyme elevations during therapy and with rare instances of acute, clinically apparent injury. (nih.gov)
- Altretamine therapy is associated with a low rate of serum enzyme elevations, but these are generally mild and self limited, not requiring dose adjustment. (nih.gov)
Allergic1
- Tell your doctor if you have ever had any unusual or allergic reaction to Altretamine or any other medicines. (anticancercure.com)
Severe2
- Altretamine may cause severe nerve damage. (medlineplus.gov)
- Severe orthostatic hypotension with altretamine. (medicscientist.com)
Liver4
- Rare instances of clinically apparent acute liver injury attributed to altretamine have been reported, but the clinical features have not been characterized. (nih.gov)
- The cause of the idiosyncratic liver injury associated with altretamine use is probably related to a hypersensitivity reaction to a hepatic metabolite of the drug, which is extensively metabolized by the liver. (nih.gov)
- Liver injury is very rare after altretamine therapy. (nih.gov)
- In situations of acute liver injury after altretamine use, rechallenge should be avoided. (nih.gov)
Dose2
- Your doctor may adjust your dose of altretamine depending on your response to treatment and any side effects that you experience. (medlineplus.gov)
- For best results, it is important to receive each scheduled dose of Altretamine medication as instructed. (anticancercure.com)
Bone marrow supp1
- Altretamine shares common side effects with other alkylating agents such as nausea, vomiting, diarrhea, alopecia, bone marrow suppression, peripheral neuropathy and rash. (nih.gov)
Medicines1
- Altretamine belongs to the general group of medicines called antineoplastics. (anticancercure.com)
Effects10
- Altretamine may cause side effects. (medlineplus.gov)
- Most side effects from Altretamine are common, but a few can be serious. (anticancercure.com)
- These are not all the possible side effects of Altretamine cancer medicine. (anticancercure.com)
- To learn more about possible side effects of Cantret (Altretamine), read the drug label or package insert or talk to your health care provider. (anticancercure.com)
- altretamine decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. (medscape.com)
- Altretamine produces anti-cancer effects through several possible mechanisms. (thegiconnection.com)
- What are the most common (occur in 30% or more of patients) side effects of treatment with altretamine? (thegiconnection.com)
- What are the less common (occur in 10% to 29% of patients) side effects of treatment with altretamine? (thegiconnection.com)
- Altretamine: minor in the numerous adverse effects, oral candidiasis. (michiganslipandfalllawyers.com)
- Polynerv™ 1000 tablet may reduce the effects of levodopa and altretamine. (svmoregroup.com)
Cancer1
- Altretamine is used to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) that has not improved or that has worsened after treatment with other medications. (medlineplus.gov)
Treatment1
- Your doctor will order certain tests before and during your treatment to check your body's response to altretamine. (medlineplus.gov)
Combination2
- The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Altretamine. (drugbank.com)
- The therapeutic efficacy of Palifermin can be decreased when used in combination with Altretamine. (drugbank.com)
Patients2
- Typically, patients are instructed to take altretamine in divided doses following a meal and at bedtime. (thegiconnection.com)
- Patients will usually have scheduled meetings with their healthcare provider while they are being treated with altretamine. (thegiconnection.com)
Articles1
- Altretamine is part of WikiMD's free ^articles! (wikimd.org)
Results1
- The DNA damage caused by altretamine results in inhibition of cellular growth and/or cellular death. (thegiconnection.com)
Time1
- Take altretamine at around the same time every day. (medlineplus.gov)
Update1
- Sign up for a monthly update of the latest Altretamine prices. (pharmacychecker.com)